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SUMMARY
A novel molecular approach to enhance the antitumour activity of 
Topoisomerase  1  (TOP1)  inhibitors  relies  on  the  use  of  chemical 
inhibitors  of  poly(ADP-ribose)  polymerase  (PARP).  Poly(ADP-
ribosyl)ation is involved in the regulation of several cellular process such 
as  DNA repair,  cell  cycle  progression  and  cell  death.  The  molecular 
mechanism  underlying  tumor  chemosensitization  to  TOP1  poisons  by 
PARP inhibitors have been in part clarified by recent findings showing 
that  poly(ADP-ribosyl)ated  PARP-1  and  PARP-2  counteract 
camptothecin  action  facilitating  resealing  of  DNA  strand  breaks. 
Moreover,  repair  of DNA strand breaks induced by poisoned TOP1 is 
slower in the presence of PARP inhibitors, leading to increased toxicity.
In the present study, we compared the effects of the camptothecin 
derivative  Topotecan (TPT)  and the  second-generation  PARP inhibitor 
PJ34, administered as single agents or in combination, in cervix (HeLa) 
and breast (MCF7) carcinoma cells, both BRCA1/2+/+ and p53+/+.
The  two  cell  lines  gave  similar  results:  (i)  TPT-dependent  cell 
growth inhibition  and cell  cycle  perturbation  were incremented  by the 
presence of PJ34; (ii) higher levels of DNA strand breaks were found in 
cells  subjected  to  TPT+PJ34 combined treatment;  (iii)  PARP-1 and -2 
modification  was  evident  in  TPT-treated  cells  and  was  reduced  by 
TPT+PJ34  combined  treatment;  (iv)  concomitantly,  a  reduction  of 
soluble/active TOP1 was observed. Likewise, PARP-1 shRNA HeLa cells 
showed increased TPT-dependent cytotoxicity and DNA damage in the 
presence of PJ34. Furthermore, TPT-dependent induction of p53 and p21 
was found 24-72 h after treatment and PJ34 further increased p53 levels 
either in PARP-1 proficient  and silenced cells.  Finally,  TPT-dependent 
onset of the apoptosis was also incremented by PARP inhibitor as shown 
by the PARP-1 proteolysis, Bax and active-caspase 3 expression.
The characterization of such signaling network can be relevant to a 
strategy to overcome acquired TOP1-poisoned chemoresistance.
RIASSUNTO
Una  nuova  strategia  molecolare  che  incrementa  l’azione 
antitumorale  degli  inibitori  della  Topoisomerasi  1  (TOP1)  si  basa 
sull’utilizzo di inibitori  delle  poli(ADP-ribosio) polimerasi  (PARP).  La 
poly(ADP-ribosil)azione è una modifica post-traduzionale coinvolta nella 
regolazione di diversi processi come il riparo del DNA, la progressione 
del  ciclo  cellulare  e  la  morte  cellulare.  Il  meccanismo molecolare  che 
sottende la chemiosensibilizzazione dei veleni di TOP1 in presenza degli 
inibitori di PARP è in parte spiegato dal fatto che PARP-1 e -2, in forma 
modificata, interagiscono con il complesso DNA-TOP1-inibitori di TOP1 
promuovendo un rapido rilascio di TOP1 dal DNA. Inoltre, il riparo delle 
rotture sul DNA indotte dai veleni di TOP1 è meno efficiente in presenza 
degli  inibitori  di  PARP,  che  incrementano  quindi  la  citotossicità 
dell’agente chemioterapico.
Nel presente studio, abbiamo comparato gli effetti dell’inibitore di 
TOP1 Topotecano (TPT) e  dell’inibitore  di  PARP PJ34,  somministrati 
come  singoli  agenti  o  in  combinazione  in  cellule  di  carcinoma  della 
cervice uterina (HeLa) e della mammella (MCF7), entrambe BRCA1/2+/+ 
e p53+/+. Sono state anche analizzate cellule HeLa silenziate stabilmente 
per PARP-1 mediante siRNA (denominate HeLaSiP-1).
Le due linee cellulari mostrano risultati simili: (i) l’inibizione della 
crescita  cellulare e la perturbazione del ciclo cellulare indotte dal TPT 
sono incrementate in presenza del PJ34; (ii) alti livelli di danno al DNA 
sono stati riscontrati in seguito al trattamento combinato TPT+PJ34; (iv) 
l’attivazione di PARP-1 e -2 è stata evidenziata nelle cellule trattate con 
TPT e ridotta dall’aggiunta del PJ34.  In particolare, le cellule HeLaSiP-1 
mostrano elevati livelli di danno al DNA ed una citotossicità maggiore, 
dipendente dal TPT, in presenza di PJ34.
E’ stata inoltre riscontrata  un’induzione dell’espressione di p53 e 
p21 TPT-dipendenti 24-72 h dal trattamento, ulterioremente incrementata 
dal PJ34, sia in cellule proficienti che deficienti per PARP-1. Infine, il 
PJ34 è in grado di aumentare l’apoptosi indotta dal TPT, evidenziato dalla 
proteolisi di PARP-1 e dalla espressione di BAX e della forma attiva della 
caspasi 3.
La caratterizzazione della segnalazione del danno indotto dal TPT 
può  essere  utile  per  mettere  a  punto  strategie  che  superino  la 
chemioresistenza acquisita  in seguito al  trattamento con gli  inibitori  di 
TOP1.
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Introduction
1. INTRODUCTION
1.1  Poly(ADP-ribose)  polymerase  (PARP)  and  Topoisomerse  1 
(TOP1) role on DNA damage repair
DNA damage signaling is crucial for the maintenance of genome 
integrity.  In  higher  eukaryotes  a  NAD+-dependent  signal  transduction 
mechanism is evolved to protect cells against the genome destabilizing 
effects of DNA strand breaks. 
The mechanism involves two nuclear enzymes,  poly(ADP-ribose) 
polymerase-1  and  -2  (PARP-1  and  PARP-2),  that  participate  to 
poly(ADP-ribosyl)ation  reaction,  a  post-translational  modification 
process which plays a critical role in different cellular functions such as 
DNA damage detection and repair, transcriptional regulation, chromatin 
modification, and cell death. PARP-1 and -2 bind to DNA strand breaks 
and form a catalytically active dimer; nicked DNA is stabilized in a V-
shaped conformation. Activated PARPs cleave  -NAD+ in nicotinamide 
and ADP-ribose to link long and branched (ADP-ribose) polymers (PAR) 
to glutamic acid residues within the primary sequence of PARP-1 and 
PARP-2  (automodification)  and  to  other  nuclear  proteins 
(heteromodification) like histones, repair proteins, DNA Topoisomerase 
1, p53.
ADP-ribose units are linked by  (1’’-2’) ribosyl-ribose glycosidic 
bonds  in  the  linear  portions  of  the  polymer  or  by  (1’’’-2’’)  ribosyl-
ribose glycosidic linkages at the branching points; their number ranges 
from a few to over 200 and branching frequency is estimated to be 2%-
3% (Figure 1).
In DNA-damaged cells, increased poly(ADP-ribose) synthesis due 
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to PARP-1 and -2 activation is paralleled by an accelerated catabolism 
that  reduces  polymer  half  life  from  several  hours  to  a  few  seconds. 
Poly(ADP-ribose) glycohydrolase (PARG) is responsible for the specific 
degradation  of  polymers  to  monomeric  ADP-ribose  units  and  ADP-
ribosyl protein lyase cleaves the link between the first ADP-ribose and 
modified aminoacids (Malanga et al, 2005).
Figure 1. The poly(ADP-ribosyl)ation reaction.
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PARP-1 and PARP-2 are members of a large family of enzymes 
with homologous catalytic domain but with otherwise distinct structures, 
functions and localizations.
PARP-1 is a 113 kDa nuclear protein comprised of three functional 
domains:
-  the  N-terminal  DNA-binding  domain  (DBD)  contains  the  nuclear 
localization signal (NLS) and two zinc fingers that are important for the 
binding  of  PARP-1  to  single-strand  breaks  (SSBs)  and  double  strand 
breaks (DSBs). A third zinc finger was found to be dispensable for DNA 
binding  and is  important  for  coupling  damage-induced  changes  in  the 
DBD to alterations in catalytic domain;
- in the central  automodification domain,  specific glutamate and lysine 
residues serve as PAR acceptors. This domain also comprises a BRCA1 
carboxy-terminal  (BRCT)  repeat  motif,  a  protein-protein  interaction 
domain that is found in other components of the DNA damage response 
pathway;
- the C-terminal catalytic domain transfers ADP-ribose subunits from -
NAD+ to protein acceptors.
Some of these recruited proteins bind covalently to polymers,  whereas 
others  are  indirectly  recruited  because  they  contain  a  PAR-binding 
consensus sequence. At the same time, the formation of PAR reduces the 
affinity  of PARP-1 and histones for DNA, a mechanism for removing 
PARP-1 from damaged sites and for the local modulation of chromatin 
compaction. The removal of PARP-1 provides access for repair proteins, 
but  the  enzyme  remains  in  the  vicinity  of  the  breaks,  recruiting  other 
selected proteins into multiprotein complexes to accelerate DNA damage 
repair (Rouleau et al; 2010). In contrast, when DNA damage exceeds cell 
3
Introduction
repair capacity,  PARP-1 undergoes cleavage by caspases (3 and 7) into 
two fragments of 89 kDa and of 24 kDa, thereby avoiding futile cycling 
of PAR that would otherwise deplete the cell of -NAD+ required for the 
onset of apoptosis (Scovassi et al; 1999).
PARP-2 is  a 62 kDa nuclear  protein,  also able  to  catalyze  DNA 
damage-dependent  automodification  and can  homo-  or  hetero-dimerize 
with PARP-1 (Figure 2). Although PARP-2 accounts for only 10-15% of 
the cellular poly(ADP-ribosyl)ation capacity under genotoxic stress, it can 
partially  compensate  for  PARP-1  loss  in  knock-out  mice  (Amè  et  al;  
1999).
The  N-terminal  domain  of  PARP-2  contains  NLS,  the  nucleolar 
localization signal (NoLS) and a highly basic DBD, that is structurally 
different  from  that  of  PARP-1,  probably  reflecting  differences  in  the 
DNA structures recognized by each enzyme (Figure 2). 
Figure 2. Structure of PARP-1 and PARP-2.
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PARP-1  and  -2  catalytic  domains  exhibit  69%  similarity;  in 
particular, PARP-2 contains an additional three aminoacid insertion that 
could  reflect  specificities  in  the  substrates  ADP-ribosylated  by  this 
enzyme (Yelamos et al; 2008).
PARP-1 and PARP-2 play a dual role as damage sensors and signal 
transducers to down-stream effectors (Figure 3). 
Figure 3. PARP-dependent signaling of DNA strand breaks.
Both proteins share several common nuclear binding partners and 
have been described as contributors to base excision repair (BER). 
In  fact,  like  PARP-1,  PARP-2 interacts  with  X-ray  repair  cross-
5
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complementing  1  (XRCC1),  DNA polymerase   and  DNA ligase  III, 
which are involved in BER  (Schreiber et al; 2002). However, PARP-1 
and -2 were shown to accumulate with different kinetics at laser-induced 
SSBs: whereas PARP-1 accumulates fast and transiently, PARP-2 shows 
a delayed and persistent accumulation at repair sites (Mortusewicz et al;  
2007).
As  mentioned  above,  PARP-1  binds  SSBs  while  PARP-2  has  a 
higher  affinity  for  gaps  and  flaps,  structures  that  correspond  to  more 
advanced repair intermediates. Taken together, these evidences favour an 
implication of PARP-2 at later steps of the repair process.
PARP-1 is also involved in DSBs repair process. 
Eukaryotes  have  two  pathways  for  repairing  DSBs:  homologous 
recombination  (HR)  and  non  homologous  end  joining  (NHEJ).  The 
relative contribution of these two DSBs repair pathways seems to differ 
depending on the cell cycle phase: HR acts mainly in the S and G2 phases 
and NHEJ mostly in the G1 phase (Khanna et al; 2001).
In regard HR, a functional and physical interaction between ataxia 
telangiectasia mutated (ATM) and PARP-1 has been described (Haince et  
al;  2007);  recently,  it  has  been  also  shown  that  PARP-1  is  able  to 
accumulate  at  a  locally  induced  DSBs  and  is  required  for  the 
accumulation of other DSBs sensors, such as meiotic recombination 11 
(MRE11) and Nijmengen breakage syndrome 1 (NBS1) proteins (Haince  
et al; 2008). Indeed, PARP-1 is reported to interact with and poly(ADP-
ribosyl)ate the DNA-PK subunit Ku, an important factor of the alternative 
pathway NHEJ (Wang et al; 2006).
The role of PARP-2 in DSBs repair still remains to be clarified: it 
has been  observed  an interaction between PARP-2 and Ku. An early 
6
Introduction
embryonic  lethality  of  PARP-2-/- ATM-/-  mice  is  a  consequence  of  the 
inefficient  BER,  leading  to  conversion  of  unrepaired  SSBs  to  DSBs 
during replication (Huber et al; 2004).
PARP-1  also  affects  DSBs  repair  as  indicated  by  the  increased 
sensitivity of PARP-1-deficient cells to DSB-inducing agents, especially 
to TOP1 inhibitors.
DNA Topoisomerase 1 (TOP1) is a ubiquitous enzyme that plays 
multiple functions at the crossroads between replication, transcription and 
mRNA  maturation.  TOP1  relaxes  DNA  supercoiling  generated  by 
transcription, replication and chromatin remodeling.
The catalytic  cycle  of TOP1 starts with the formation of a DNA 
single-strand break after which it covalently binds to the 3’-end of the 
DNA phosphodiester backbone, forming TOP1-DNA cleavable complex 
(Figure 4). These complexes are reversible intermediates catalyzing the 
religation reaction of the enzyme.
RELIGATION
TPT
TOP1
CLEAVABLE 
COMPLEX
ABORTIVE 
COMPLEX
DNA 
REPLICATION
Figure 4. TOP1 catalitic cycle.
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Camptothecin  (CPT),  the  prototype  of  TOP1  inhibitors,  and  its 
derivatives  such as the clinically  relevant  drug Topotecan stabilize the 
cleavable complex in the  abortive complex, and thus prevents religation 
step of the enzyme catalytic cycle, generating an accumulation of SSBs. 
The cytotoxic mechanism of camptothecins is largely S-phase dependent, 
indicating that is triggered by a collision between replication fork and the 
abortive complex.  This may result  in blockage of fork movement,  and 
finally, the formation of DNA DSBs (Tomicic et al; 2005). 
The camptothecin derivative Topotecan (TPT) is approved for the 
treatment of ovarian cancer, non small-cell lung cancer and under clinical 
investigation for a number of advanced solid tumors and haematological 
malignancies (Pommier et al; 2006).
For  the  reason  that  HR  is  S  phase-dependent,  TOP1  poisons-
induced  replication-dependent  DSBs  are  usually  repaired  by  the  HR 
pathway.
It is known that PARP inhibitors increase the cytotoxic effects of 
TPT.  Furthermore,  the  molecular  mechanism  underlying  tumor 
chemosensitization to TOP1 poisons by PARP inhibitors has been in part 
clarified  by  recent  findings  showing  that  PARP-1  and  -2,  in  their 
automodified form, counteract camptothecin-action facilitating resealing 
of  DNA  strand  breaks.  This  occurs  trough  non-covalent  yet  specific 
interaction of PAR with particular TOP1 sites which results in inhibition 
of DNA cleavage and stimulation of the religation reaction  (Malanga et  
al; 2004). 
The  potential  of  PARP  inhibitors  to  increase  the  efficacy  of 
chemotherapy has  led to  the development  of  a  wide  range of  specific 
inhibitors  – quinazolinone derivatives  – like NU1025 and PJ34, which 
8
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display increased potency compared to the prototype 3-aminobenzamide 
(3-ABA) (Sandhu et al; 2010).
In this regard, it has been previously demonstrated a TPT-dependent 
PARP-1  activation  in  glioblastoma  cells,  while  co-treatment  with  the 
PARP inhibitor  NU1025 increased a TPT-dependent  p53 up-regulation 
(Cimmino et  al;  2007).  Indeed, PARP inhibitors  enhance the action of 
several SSBs-inducing agents, like alkylating agents (i.e. temozolomide) 
in tumor cell lines and in human tumors. This approach indicates a pairing 
PARP  inhibitors  with  DNA-damaging  therapy  to  achieve 
chemosensitization (Rouleau et al; 2010).
It has been reported that BRCA1/2 mutated breast carcinoma cells 
lost their ability to repair DNA breaks after PARP inhibition, which can 
result in cell cycle arrest and apoptosis, considering that BRCA proteins 
are critical for the HR pathway (Bryant et al; 2005). This specific killing 
of tumor cells  led to PARP inhibitors entering clinical trials  of repair-
deficient tumors.
Furthermore,  a  factor  supposed  to  involved  in  determining  the 
sensitivity of cells to TOP1 inhibitor is p53. However, for breast cancer 
cells  the  p53  status  is  not  found  to  be  predictive  for  sensitivity  to 
camptothecins (Davis et al; 1998).
1.2 Aim of the work
From the mean of such evidences, we have investigated the role of 
PARP-1 and PARP-2 in the DNA damage response to TOP1 inhibitor, 
TPT, in human BRCA1/2+/+ and p53+/+ breast (MCF7) and cervix (HeLa) 
carcinoma  cells  treated  with  TPT,  administered  as  single  agent  or  in 
9
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combination with a PARP inhibitor, PJ34. Furthermore, TPT-sensitivity 
of  HeLa  cells  in  which  PARP-1  has  been  knocked  down  by  RNA 
interference, has been compared to that of HeLa cells with PJ34.
10
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2. MATERIALS AND METHODS 
2.1 Drugs, antibodies and chemicals
TPT and CPT were from Glaxo Smith-Kline, PJ34 [N-(6-oxo-5,6,-
dihydrophenanthridin-2-yl)-(N,Ndimethylamino)Acetamide]  and  3-ABA 
were from  Alexis Biochemicals. The cocktail of protease inhibitors was 
from ROCHE-Diagnostic.
Nicotinamide  adenine  [adenylate-32P]  dinucleotide  –  [32P]-NAD+ 
(1,000 Ci/mmole, 10 mCi/ml) was supplied by GE Healthcare.
Propidium iodide (PI) and RNAse were from Sigma-Aldrich.
PVDF (poly-vinylidene-fluoride) membrane was from MILLIPORE 
S.p.A. Anti-PARP-1 mouse monoclonal (F1-23) and anti-PARP-2 rabbit 
polyclonal  (Yuc)  antibodies  were from  Alexis  Biochemicals,  anti-DNA 
Topoisomerase  1  human  rabbit  polyclonal  antibody  (Scl-70)  from 
Topogen and anti-H2AX rabbit polyclonal antibody (ser139, 2577) from 
Cell Signaling. Anti-p53 (DO-1), anti-p21 (C-19), anti-Bax (P-19), anti-
AIF (E-1),  anti-GAPDH (H-2) mouse  monoclonal  antibodies  and anti-
Caspase  3  rabbit  polyclonal  antibody  (H-277)  were  from  Santa-Cruz  
Biotecnology.  Anti-actin  (A2066)  rabbit  polyclonal  antibody  and  goat 
anti-mouse  and  goat  anti-rabbit  IgG  HRP-conjugated  antibodies  were 
from Sigma-Aldrich.
All other chemicals were of highest quality commercially avaible.
2.2 Cell cultures
Cervix (HeLa) and breast (MCF7) carcinoma cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) 
heat-inactivated foetal bovine serum (FBS), 100 U/ml penicillin, 100 g/ml 
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streptomycin, 5 mM L-glutamine and incubated at 37°C in a humidified 
atmosphere, plus 5% CO2.
Stably   PARP-1  silenced  HeLa  cells   (hereafter  referred  to  as 
HeLaSiP-1)  or  trasfected  with  pBabe  vector  carrying  the  puromycin 
resistance  gene  (hereafter  referred  to  as  HeLaBabe)  were  obtained  as 
previously described (Tentori et al; 2010).
2.3 Cell growth inhibition
MCF7 and HeLa cells were seeded at 1x106 cells; after 24 h, cell 
cultures were treated with graded concentration of TPT and PJ34 (or 3-
ABA) and cell growth inhibition was assessed at different time points (24, 
48, 72 h) using trypan blue staining. All the experiments were performed 
in triplicate.
2.4 Cytofluorimetric analysis
Control  and  treated  cells  were  detached  by  enzymatic  treatment 
(Trypsin/EDTA  0.02%),  washed  in  PBS  w/o  Ca2+/Mg2+ pooled  with 
floating cells and recovered by centrifugation at 1,200 rpm for 15 min at 
4°C. Cells were fixed in 70% ethanol and stored at -20°C until analysis. 
After  washing  in  PBS  w/o  Ca2+/Mg2+,  cells  were  stained  in  2  ml  of 
propidium iodide  (PI)  staining  solution  [50  g/ml  of  PI,  1  mg/ml  of 
RNAse A, 1% Triton X-100 in PBS w/o Ca2+/Mg2+, pH 7.4] overnight at 
4°C and DNA flow cytometry was performed in duplicate by a FACScan 
flow  cytometer  (Becton  Dickinson  Franklin  Lakes)  coupled  with  a 
CICERO work station (Cytomation). Cell cycle analysis was performed 
by the ModFit LT software (Verity Software House Inc. Topsham). FL2 
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area versus FL2 width gating was done to exclude doublets from G2/M 
region. For each sample 15,000 events were stored in list mode file.
2.5 Alkaline Comet Assay
Cells were suspended in PBS at a density of 104 cells/ml and mixed 
with an equal volume of fresh low-melting agarose (LMA, 1% in PBS); 
80  l of agarose cell suspension was spread on normal-melting agarose 
(NMA, 1% in PBS) slides and covered with a cover-slip. Two slides were 
prepared per sample. After gelling for 5 min on an ice bed, the cover-slip 
was  gently  removed  and  another  layer  was  added,  cover-slipped  and 
allowed to solidify for 5 min on ice before gently removing the cover-slip. 
The  slides  were  then  immersed  in  a  freshly  prepared  ice-cold  lysis 
solution (2.5 M NaCl, 0.1 M Na2EDTA, 0.01 M Tris, 1% Triton X-100, 
10% DMSO, pH 10) for 1 h. The slides were drained and placed in a 
horizontal electrophoresis tank filled with freshly prepared alkaline buffer 
(0.3 M NaOH, 1 mM Na2EDTA, pH 13) and electrophoresis carried out 
for 20 min at 300 mA. Finally, the slides were gently washed twice in a 
neutralization buffer (Tris-HCl 0.4 M, pH 7.5) for 5 minutes to remove 
alkali and detergent, and stained with 50  l/ml DAPI (3h). Images of a 
minimum  of  hundred  cells  from  each  sample  were  analysed  on  a 
fluorescence microscope (Nikon Instruments S.p.A.); overlapping figures 
were avoided from each slide. Quantitative assessment of DNA damage 
was  performed  using  Comet  Score  1.5  Image  Analysis  (TriTek 
Corporation)  software,  which computes  the integrated  intensity  profile 
for  each  cell.  DNA damage was measured  as olive tail  moment  value 
[(Tail  mean  -  Head  mean)  x  %  DNA  in  tail/100].  The  results  were 
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analysed by Student’s t-test and were considered statistically significant at 
P<0.008.
2.6 Analysis of [32P]-PAR synthesis 
Following  treatment  with  10  M +/-  5  M PJ34 of  intact  cells 
(5x106 cells/plate),  [32P]-PAR synthesis  was determined by substituting 
the  culture  medium  with  1  ml  of  56  mM  HEPES  buffer  pH  7.5, 
containing 28 mM KCl, 28 mM NaCl, 2 mM MgCl2, 0.01% digitonin, 0.1 
mM PMSF, 1:25 dilution of a cocktail of protease inhibitors, 0.125 M 
[32P]-NAD+ (1,000 Ci/mmole). After incubation at 37°C for 30 min, cells 
were scraped off the plates, transferred to eppendorf tubes and mixed with 
TCA at  20% (w/v)  final  concentration.  After  15  min  standing on ice, 
samples were collected by centrifugation at 1,200 rpm for 15 min, washed 
twice with 5% TCA and three times with ethanol. [32P]-PAR incorporated 
in the TCA-insoluble fraction was measured by Cerenkov counting using 
a  LS8100  liquid  scintillation  spectrometer  (Beckman  Coulter  S.p.A.). 
Finally,  TCA  protein  pellets  were  resuspended  in  Laemmli  buffer; 
proteins were separated by 5-15% SDS-PAGE and after electroblotting on 
PVDF  membrane,  [32P]-PAR  acceptors  were  visualized  by 
autoradiography. Immunodetection of specific proteins was accomplished 
on the same blots after autoradiography.
PJ34  efficacy  as  PARP  inhibitor  was  determined  in  an  in  vitro 
enzymatic  activity  assay  using  permeabilized  cells:  cell  pellets  were 
resuspended in 40 mM Tris-HCl pH 7.8, 0.6 mM EDTA, 30 mM MgCl2, 
0.05%  Triton  X-100,  1mM  -mercaptoethanol,  20%  glycerol,  1  mM 
PMSF  and  1:25  dilution  of  the  cocktail  of  protease.  To  maximally 
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stimulate PAR synthesis, DNA strand breaks were induced by sonication 
for 30 sec at medium intensity; finally, samples were incubated at 30°C 
for 1 h with 5Ci/ml [32P]-NAD+ and 50  M unlabeled  -NAD+, in the 
presence  or  absence  of  5  M PJ34.  Reactions  were  stopped by TCA 
addition (20% final concentration) and the samples were processed and 
analysed as described above.
2.7 Isolation of nuclear and post-nuclear fractions
To isolate sub-cellular fractions, cells were suspended in a buffer 
containing 30 mM Tris-HCl pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 1% 
Triton  X-100,  20% glycerol,  2  mM PMSF and the  protease  inhibitors 
cocktail solution. After 30 min of incubation on ice, cellular suspensions 
were centrifuged at 960 x g for 90 sec at 4°C and the nuclear fractions 
recovered  in  the  pellet.  The  supernatant  represents  the  post-nuclear 
fraction. 
Nuclear  fractions  were  resuspended  in  20  mM  HEPES  pH  7.9, 
containing 20 mM KCl,  0.2 mM EDTA, 1.5 mM MgCl2, 25% glycerol 
and  0.2  mM  PMSF.  Protein  concentration  was  determined  using  the 
Bradford protein assay reagent (BIO-RAD) with bovine serum albumin 
(BSA) as a standard.
2.8 Autoradiographic and immunological analyses
Aliquots  of  120  g of  cellular  proteins  were  separated  by SDS-
PAGE (5-15% gradient  gels)  and transferred  onto  a  PVDF membrane 
using  an  electroblotting  apparatus  (BIO-RAD).  The  membrane  was 
subjected to autoradiographic analysis by the PhosphorImager (BIO-RAD) 
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and/or to immunodetection after blocking with 3% BSA in TBST 1 h, 
with anti-PARP-1 (diluted 1:5,000), anti-PARP-2 (diluted 1:5,000), anti-
TOP1  (diluted  1:2,500),  anti-p53  (diluted  1:5,000),  anti-p21  (diluted 
1:1,000), anti-Bax (diluted 1:500), anti-AIF (diluted 1:500), anti-Caspase 
3  (diluted  1:500),  anti-GAPDH (diluted  1:5,000),  anti-H2AX (diluted 
1:1,000) or anti-actin (diluted 1:1,000).
As  secondary  antibodies  goat-anti-mouse  or  goat-anti-rabbit  IgG 
HRP-conjugate (diluted 1:10,000-1:20,000) in 3% (w/v) non-fat milk in 
TBST  were  used.  Peroxidase  activity  was  detected  using  the  ECL 
Advance Western Blotting Kit (GE Healthcare) and quantified using the 
Immuno-Star Chemiluminescent detection system GS710 (BIO-RAD) and 
the Arbitrary Densitometric  Units  normalized on those of the GAPDH 
loading control.
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3. RESULTS
3.1 Effect of PARP inhibitors on TPT-induced growth inhibition and 
cell cycle distribution in human carcinoma cells
In preliminary experiments, we evaluated a dose-response of MCF7 
cells  to  TPT,  alone  or  in  combination  with  5  M  PJ34  at  24-48  h 
treatment. As shown in  Figure 5, TPT alone caused a strong cytotoxic 
effect  at  24  h,  starting  from  5  M  concentration  (60%  cell  growth 
inhibition),  while  the  same  amount  of  PJ34  and  1  M  TPT  slightly 
affected cell growth inhibition (18%). Therefore, in this condition it was 
difficult to evaluate additive/synergic effect of combined treatment.
Figure 5. Dose-dependece response of MCF7 cells to TPT in presence 
or absence PJ34.
MCF7 cells were treated for 24 - 48 h with TPT (1 – 5 – 10 M) in combination 
or not with PJ34 (5 M). The results are the mean of three different experiments 
giving similar results.
For  further  experiments  we  set  up  1  h  treatment  condition  with 
10 M TPT followed by different recovery times in the presence or not of 
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5 M PJ34. Furthermore, stably PARP-1 silenced HeLa cells (HeLaSiP-1) 
were also compared to PARP-1 proficient HeLa cells (HeLaBabe).
Both HeLaBabe and  MCF7 cells  showed  till  72  h  after  treatment 
mainly a cytostatic effect (Figure 6), whereas PARP-1 silencing rendered 
HeLaSiP-1 cells  more  sensitive  to the drug, causing 45% of cells  to die 
(Figure 7).  The  presence  of  PARP inhibitor  during the  recovery time 
seemed to increase TPT-toxicity, also in PARP-1 deficient cells. 
Figure 6. Cell growth inhibition of MCF7 and HeLaBabe cells treated 
with TPT and PJ34 as single agents or in combination.
The cells were treated for 1 h with 10 M TPT+/- 5 M PJ34 and left to recover 
24, 48 e 72 h in fresh medium in the presence or not of PARP inhibitor. The 
results are the mean of three different experiments giving similar results.
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Figure 7. Cell growth inhibition of HeLaSiP-1 cells treated with TPT 
and PJ34 as single agents or in combination.
The cells were treated for 1 h with 10 M TPT+/- 5 M PJ34 and left to recover 
24, 48 e 72 h in fresh medium in the presence or not of PJ34. The results are the  
mean of three different experiments giving similar results.
Figure 8 shows a comparison of cell growth inhibition determined 
in  MCF7 cells  by treatment  with  TOP1 inhibitors  (CPT and TPT)  as 
single agents at the same concentration or in combination with PJ34 or 
3-ABA. By the all of the results we observed an additive effect of the 
PARP inhibitors on the cytostatic effect of TPT. Interestingly, the same 
increment on cell  growth inhibition was observed by a 200 times dose 
reduction of PJ34 with respect to 3-ABA.
CPT, instead, caused a cytotoxic effect per se, even higher than that 
determined  by  TPT+PJ34  (or  3-ABA)  combination.  Therefore,  no 
additive effect was observed by PJ34 and 3-ABA on CPT-action.
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Figure 8. Comparison of TPT and CPT as single agents or combined 
with PARP inhibitors.
MCF7 cells were treated for 1 h with 10 M TPT or 10 M CPT +/- 5M PJ34 
or 1mM 3-ABA and left to recover 24 h in fresh medium in the presence or not 
of PJ34 or 3-ABA. The results are expressed as percentages of growth inhibition 
+/- S.E.
To go better inside into the mechanism of enhanced TPT-toxicity as 
a consequence of alteration of the cellular poly(ADP-ribosyl)ation status, 
we  analysed  cell  cycle  distribution  24  h  after  1  h  treatment  with 
increasing  concentrations  of  TPT  in  the  presence  or  not  of  fixed 
concentration of  5 M PJ34. 
As shown in Figure 9A, in HeLaBabe cells graded concentrations of 
TPT induced a progressive increase of cell  accumulation  in  the G2/M 
phase starting from 0.2  M up to 1.25  M; higher TPT-doses, instead, 
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caused the well known TPT-specific S phase arrest. Then, the addition of 
PJ34 to TPT-concentrations < 1.25 M significantly increased G2/M cell 
accumulation,  whereas  combined  with  > 1.25  M TPT concentrations 
induced S phase block of cells (that would escape TPT-action).
Figure 9. Cell cycle analysis of HeLa cells treated with TPT and PJ34 
as single agents or in combination.
Babe and SiP-1 cells were treated for 1 h with TPT (0.2 – 0.4 – 1.25 – 2.5 – 5  
M) +/- PJ34 (5 M) and left to recover 24 h in fresh medium in the presence or 
not of PJ34. The results are expressed as percentages of cells in the G1, S and 
G2/M phase of the cell cycle.
As shown in  Figure 10, cell cycle distribution was unaffected by 
treatment of HeLaBabe cells with 5  M PJ34 and 1 mM 3-ABA used as 
single  agents.  Moreover,  when  combined  with  1.25  M TPT 3-ABA 
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caused a  minor  S phase  accumulation  (27%) compare  to  PJ34 (78%), 
confirming the enhanced potency of this later PARP inhibitor.
Figure 10. Cell cycle analysis of HeLaBabe cells treated with TPT and 
PARP inhibitors as single agents or in combination.
Babe cells were treated for 1 h with 1.25 M TPT +/- 5 M PJ34 or 1 mM 3-
ABA and left to recover 24 h in fresh medium in the presence or not of PJ34 or 
3-ABA.  Flow cytometric  determination  of  DNA content  after  PI  staining  is 
shown. The percentage of cells in the G1, S and G2/M is indicated.
Accordingly, HeLaSiP-1 cells underwent a more pronounced increase 
of G2/M phase or S phase accumulation, with respect to HeLaBabe cells 
exposed to the same doses of TPT; interestingly,  the combination 1.25 
M TPT and 5 M PJ34 induced S phase accumulation at higher extent 
than HeLaBabe (Figure 9B).
Cytofluorimetric analysis at longer recovery times (i.e. 72 h after 1 
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h treatment)  revealed  that  the alteration  of  the poly(ADP-ribosyl)ation 
system  determined  the  induction  of  apoptosis,  as  indicated  by  the 
appearance  of  a  sub-diploid  peak.  In  particular,  the  lack  of  PARP-1 
appeared  to  be  more  effective  than  PARP  activity  inhibition  as  the 
fraction of apoptotic cells was doubled in HeLaSiP-1 treated with 1.25 M 
TPT (62%) versus HeLaBabe subjected to a combined TPT+PJ34 treatment 
(38%) (Figure 11).
Figure 11. Cell death analysis of HeLa cells subjected to TPT+/-PJ34 
treatment.
Babe and SiP-1 cells were treated for 1 h with 1.25 M TPT +/- 5 M PJ34 and 
left  to  recover  72  h  in  fresh  medium in  the  presence  or  not  of  PJ34.  Flow 
cytometric  determination  of  DNA  content  after  PI  staining  is  shown.  The 
percentage of cells in the sub-diploid (subG1) peak is indicated.
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3.2  Analysis  of  TPT-  and/or  PJ34-dependent  DNA  damage  in 
carcinoma cells
By alkaline comet assay, we analysed the level of both DNA SSBs 
and DSBs arising 24 h after 10  M TPT +/- 5 PJ34  M 1 h treatment. 
Figure 12A shows that the olive tail moment value was comparable in all 
cell lines and further increased in the cells left to recover in the presence 
of PJ34, either PARP-1 proficient or silenced cells.
Figure 12. DNA damage in carcinoma cells subjected to TPT+/- PJ34 
treatment.
A: Hundred cells 24 h after 1 h treatment with 10 M TPT +/- 5 M PJ34 were 
analysed by alkaline comet assay on a fluorescence microscope and quantitative 
assessment of DNA damage was performed using Comet Score.
B: Western blot analysis of H2AX levels in Babe and SiP-1 cell nuclei treated 
1 h with 10 M TPT and allowed to recover in fresh medium in the presence or 
not of 5 M PJ34 for 72 h. Actin was used as loading control.
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The definition  of a DSBs level was obtained by looking at H2AX 
phosphorylation in isolated nuclei from Babe and SiP-1 cells. Figure 12B 
shows a TPT-dependent increase of -H2AX in HeLa cells until 72 h after 
treatment  that  was  further  increased  after  TPT+PJ34  cotreatment. 
Interestingly,  the  further  increment  determined  by  PJ34  in  PARP-1 
silcenced cells was suggestive of the involvement of PARP-2 (or some 
other PARP).
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3.3 Analysis of PAR synthesis in carcinoma cells after treatment with 
TPT +/- PJ34
First, PJ34 efficacy as PARP inhibitor at 5  M concentration was 
assessed by an  in vitro enzyme activity assay,  carried out in sonicated 
cells incubated with exogenous 50 M [32P]-NAD+ in the presence or not 
of PJ34. Sonication was performed to induce DNA strand breaks and thus 
maximally stimulate endogenous PARP activities.
As shown in Figure 13A, a high amount of protein-bound PAR was 
produced in HeLaBabe cells and such an activity was completely abolished 
by 5 M PJ34. 
The  corresponding  immunodetection  showed  a  reduction  of 
PARP-1  native  protein  in  the  sample  incubated  with  -NAD+ alone 
compared to that incubated with  -NAD+ + PJ34. Such a difference is 
explained  by  a  band  depletion  due  to  the  automodification-related 
electrophoretic  mobility  shift  of  a  fraction  of  heavily  poly(ADP-
ribosylated)  PARP-1. After  quantification  of immunoreactive bands by 
scanning densitometry and normalization of PARP-1 to GAPDH content, 
it  could  be  estimated  that  about  50%  of  PARP-1  underwent 
automodification (Figure 13B).
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Figure 13. PJ34-dependent inhibition of PAR synthesis in HeLa cells.
Babe and SiP-1 cells were resuspended in permeabilizing buffer, sonicated and 
incubated with 50 M [32P]-NAD+ +/- 5 M PJ34, as described in M&M.
A:  Autoradiographic  analysis  of  whole  cell  protein  after  SDS-PAGE  and 
electroblot on PVDF.
B:  Immunodetection of PARP-1 and GAPDH on the blot shown in A.
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The same kind of analysis carried out on HeLaSiP-1 cells revealed a 
strongly reduced ADP-ribosylation capacity of these cells: in fact, in the 
autoradiography  only  a  light  smear  at  top  of  the  gel  was  visualized 
(Figure 13A) and by western blotting no PARP-1 was detected (Figure 
13B),  as  a  consequence  of  silencing.  This  modest  ADP-ribosylation 
activity detected (about 18%), may be due to PARP-2 (or other PARPs) 
or to a residual PARP-1 protein: anyway it was also inhibited by PJ34.
Then, we used a different experimental setting to determine whether 
or  not  TPT could  induce  PARPs  activation  in  growing  cells.  To  this 
purpose, the MCF7 cells were first exposed to the drugs and then PAR 
synthesis was measured in situ by incubation of permeabilized cells with 
0.125 M [32P]-NAD+.
The autoradiography showed a main signal up to PARP-1 molecular 
weight (113 kDa), indicating a TPT-dependent PARP-1 automodification, 
that  appeared  already  after  1  h  treatment  and  was  sustained  for  24  h 
recovery time (Figure 14).
A  minor  autoradiographic  signal  in  the  90-50  kDa  MWs  range 
could be attributed to a modified PARP-2 (62 kDa), on the basis of a 
modification-related electrophoretic mobility shift.
The  radioactive  signals  were  significantly  reduced  in  cells  co-
treated with TPT+PJ34, accordingly with a 75% decrease of the [32P]-
PAR incorporated  in  the  TCA-insoluble  fraction  with  respect  to  cells 
treated with TPT alone, measured by the use of the liquid scintillation 
spectrometer.
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Figure 14. TPT-dependent PARPs activation in MCF7 cells.
Following 1h treatment with 10 M TPT +/- 5 M PJ34 and recovery for 24 h in 
fresh medium in the presence or not of PJ34, MCF7 cells were incubated with 
0.125 M [32P]-NAD+, as described in M&M.
A:  Autoradiographic  analysis  of  whole  cell  protein  after  SDS-PAGE  and 
electroblot on PVDF.
B:  Immunodetection of PARP-1, PARP-2 and GAPDH on the blot shown in A.
Fifty  ng  of  human  recombinant  PARP-2  (hrPARP-2)  was  also  loaded  as  a 
standard.
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3.4 Immunological analysis of different protein level in TPT +/- PJ34 
treated carcinoma cells
By western blotting,  we looked  at TPT-dependent changes in the 
endogenous  levels  of  several  proteins  in  HeLa  and  MCF7  cells  at 
different times (24, 48 and 72 h) after 1 h treatment with 10 M TPT +/- 
PJ34.
Figure  15 shows  that  the  amount  of  soluble/active  TOP1  was 
lowered  till  72  h  recovery  times,  as  a  consequence  of  the  treatments. 
Conversely, it was observed an up-regulation of p53 levels in the same 
time frame and the concomitant  p53-dependent  p21 induction,  starting 
from 24 h after TPT-treatment.
The  same  results  were  evident  in  HeLa  cells  (Figure  16):  in 
particular,  the  TPT-dependent  p53  up-regulation  was  even  higher  in 
HeLaSiP-1 cells and further increased by TPT and PJ34 co-treatment, with 
respect to HeLaBabe cells.
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Figure 15. Western blot analysis of PARP-1, TOP1, p53 and p21 in 
MCF7 cells.
MCF7 cells were treated with 10 M TPT+/- 5 M PJ34 for 1 h and allowed to 
recover in fresh medium in the presence or not of PJ34 for the indicated times.  
GAPDH was used as loading control.
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Figure 16. Western blot analysis of PARP-1,  TOP1 and p53 in HeLa 
cells.
Babe and SiP-1 cells were treated with 10 M TPT+/- 5  M PJ34 for 1 h and 
allowed  to  recover  in  fresh  medium in  the  presence  or  not  of  PJ34 for  the 
indicated times. GAPDH was used as loading control.
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Indeed,  we  also  confirmed  the  p53  activation  by  looking  to  its 
nuclear  stabilization in HeLa cells.  Figure 17 shows a TPT-dependent 
increase of nuclear p53-localization arising 24 h after treatment, that was 
even higher as a consequence of PJ34 addition. 
Figure 17. p53 nuclear stabilization in HeLa cells.
Western blot analysis of p53 levels in Babe cell nuclei treated 1 h with 10 M 
TPT+/- 5 M PJ34 and allowed to recover in fresh medium in the presence or  
not of PJ34 for 24 h. Actin was used as loading control.
By densitometric scanning of immunoreactive bands of Figure 16, 
we quantified the changes in p53 levels at different times after single and 
combined treatments. 
As shown in Figure 18, 72 h after 1 h treatment, we calculated a 10 
fold increase of p53 levels in HeLaSiP-1 cells compared with 2.25 fold in 
HeLaBabe cells treated with TPT alone; these values were increased to 13 
fold and 4.5 fold in SiP-1 and Babe respectively, by the presence of PJ34 
during the recovery time.
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Figure 18. Densitometric analysis of p53 levels in HeLa cells.
After  immunodetection on western blot,  band  intensities were quantified by 
scanning  densitometry.  Data,  expressed  as  Arbitrary  Densitometric  Units 
(ADU), were normalized to the internal control GAPDH.
Finally,  at  longer  recovery  times  we  analysed  the  expression  of 
apoptotic markers. 
As  shown  in  Figure  19A,  in  HeLaBabe cells  it  was  evident  the 
caspase-dependent PARP-1 cleavage. Instead, in MCF7 cells the PARP-1 
apoptotic  fragment  was  hardly  detectable,  but  we  observed  the  p53-
dependent BAX expression. Interestingly, we found that PJ34 was able to 
enhance both such apoptotic signals.
Moreover, we looked for other apoptotic markers in isolated nuclei 
of HeLaSiP-1 cells. 
In Figure 19B, it couldn’t observed any nuclear traslocation of AIF 
(Apoptosis-Inducing Factor) in treated cells, but it was evident the active 
form  of  caspase  3  in  nuclei  from  TPT-treated  cells,  incremented  by 
TPT+PJ34 combined treatment.
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Figure 19. Apoptotic markers in carcinoma cells.
Cells were treated with 10 M TPT+/- 5 M PJ34 for 1 h and allowed to recover 
in fresh medium in the presence or not of PJ34 for 72 h.
A:  Western  blot  analysis  of  PARP-1  and Bax  in  HeLaBabe and  MCF7 cells. 
GAPDH was used as loading control.
B:  Western blot analysis of AIF and Caspase 3 in HeLaSiP-1 cell nuclei. Actin 
was used as loading control.
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4. DISCUSSION
Clinical  investigation  of  PARP  inhibitors  follows  two  distinct 
approaches:  targeting  cells  that  are  genetically  predisposed  (repair-
deficient)  to  die  when  PARP  activity  is  lost;  and  combining  PARP 
inhibition with DNA-damaging therapy to derive additional therapeutic 
benefit  from  DNA  damage.  This  has  led  to  the  development  of  a 
multitude  of  potent  PARP  inhibitors  with  various  bioavailability  and 
pharmacokinetic characteristic whose efficacy in the treatment of cancer 
in vivo has been evaluated in animal models (Tentori et al; 2005).
In our studies, we used the hydrophilic PARP inhibitor PJ34 that 
has been recently reported to synergize with cisplatin in triple-negative 
breast  cancer (Hastak et al;  2010) and colon carcinoma (Gambi et  al;  
2008) cell lines, in combination with the DNA Topoisomerase 1 inhibitor 
TPT. For our experiments, we performed 1 h treatment up to 10 M TPT 
that was already reported to be sufficient for trapping TOP1 in MCF7 
cells (Feeney et al; 2003). PJ34 was used at 5 M concentration that was 
efficient at inhibiting PARP activity, while not being cytotoxic per se.We 
found that  TPT toxicity  was higher  when PAR synthesis  was strongly 
reduced  by  either  PARP-1  silencing  (HeLaSiP-1 cells)  or  PJ34 
administration  (both  in  HeLa  and  MCF7  cells),  as  indicated  by  cell 
growth and cell cycle analysis.
In  fact,  MCF7 and HeLa  cells,  according  with  their  comparable 
PARP-1+/+, BRCA1/2+/+ and p53+/+ status showed the same sensitivity to 
TPT, which determined a cytostatic effect and a cell cycle arrest until 72 
h after treatment. However, in combination with PJ34, TPT was cytotoxic 
even at a very low concentration (1.25 M). Accordingly, TPT alone was 
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cytotoxic in HeLaSiP-1. Interestingly, the PARP inhibitor further increased 
the  sensitivity  of  SiP-1  cells  treated  with  the  drug  combination, 
suggesting  a  PARP-2  involvement  in  the  signaling  of  TPT-dependent 
DNA damage. So, TPT-treated cells entered the apoptotic program as a 
consequence of PARP-1 silencing and/or PARP inhibition.
Consistently with the idea that poly(ADP-ribosyl)ation plays a role 
in the response to TPT-induced DNA damage, we found increased PAR 
synthesis  following  cell  exposure  to  10  M  TPT.  The  lack  of  PAR 
synthesis, by interfering with the repair of TOP1-induced DNA damage 
causes  DNA  strand  break  accumulation  and  further  delays  cell  cycle 
progression. 
In  particular,  we observed distinct  cell  cycle  perturbation  effects 
depending on the concentration of TOP1 poison and on the association 
with the PARP inhibitor:  PJ34 in combination with 0.2 - 0.4  M TPT 
caused more cells  to be arrested in G2/M phase,  while combined with 
1.25 M TPT induced a S phase block, not observed in TPT+3-ABA co-
treated cells. Furthermore, the G2/M arrest induced by 0.4  M TPT in 
PARP-1 wild type cells was magnified in PARP-1 silenced HeLa cells.
These evidences agree with the concept that after 1 h pulse of TPT 
not  all  the  cells  are  prevented  from entry  in  mitosis  and  the  G2 cell 
lineages could survive TPT-mediated cytotoxicity (Tuduri et al; 2009). 
Therefore, the persistence of cells at the G2/M phase provoked by PARP 
inhibition and PARP-1 silencing can be seen as a mechanism to overcome 
cell  resistance  to  camptothecin  derivates.  Interestingly,  in  PARP-1 
silenced HeLa cells PJ34 increased the TPT-dependent S phase block as 
further indication of PARP-2 implication.
Indeed, the TPT-dependent  DNA damage level  was increased by 
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co-treatment with PJ34 either in PARP-1 proficient and silenced cells 24 
h after treatment . In nuclei of such cells, differences in  H2AX levels 
deriving from TPT+/- PJ34 exposure support the involvement not only for 
PARP-1 but also for PARP-2 in the signaling of TPT-dependent DSBs 
repair.
Moreover, we found a sustained PAR synthesis from 1 to 24 h after 
treatment  and  most  of  the  newly  synthesized  polymer  was  linked  to 
PARP-1 itself.  Another PAR acceptor (probably PARP-2) in the lower 
molecular weight range appeared to be TPT-dependent. Accordingly with 
the magnified effect of TPT+PJ34 co-treatment in HeLaSiP-1, the PARP-2 
modification could represent the mechanism of its participation in DSBs 
signaling and HR repair (Yelamos at al; 2008). 
PARP activity assays also offered an indication of PJ34 inhibitory 
efficacy.  We  already  showed  that  5  M  PJ34  totally  inhibits  PARP 
activity  in  vitro;  according  with  the  in  situ assays  we  determined 
approximatively 75% PARP inhibition in permeabilised cells. This could 
also  explain  quantitative  differences  observed  in  the  use  of  inhibitors 
compared to PARP-1 silencing. Indeed, our results also confirmed that 
PJ34,  as  its  prototype  3-ABA,  do  not  discriminate  between  PARPs 
enzyme. Then, PARP-1 silenced cells allowed the attribution of a residual 
PARP activity (12%) to PARP-2.
The  last  set  of  results  was  based  on  mechanistic  investigations 
addressed to show the long-term response to TPT action: after 1 h pulse 
TOP1 soluble/active fraction was drastically reduced for at least  3 cell 
duplication cycle,  otherwise p53 levels increased within the same time 
frame. Such an up-regulation was even higher in cell lacking PARP-1 and 
further  increased  by  TPT+PJ34  treatment,  supporting  again  the 
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involvement of PARP-2 in the signaling of TPT-dependent DNA damage. 
These results are in agreement with those previously reported in the same 
cells  treated  with  the  methylating  agent  temozolomide  in  combination 
with the PARP inhibitor GPI 15427, suggesting the implication of PARP-
2 in the repair  of another DNA  damage-inducing agent (Tentori et  al;  
2010).
We  also  observed  that caspase  3  activation,  caspase-dependent 
PARP-1 proteolysis and p53-dependent BAX expression were sustained 
by the PARP inhibitor as a result of apoptosis induction.
By the all of such evidences, we envisaged a TPT-dependent DNA 
damage signaling network, involving PARPs. In fact, the DNA damage 
arising from the trapping of TOP1 was signaled by PARP-1 and -2 and 
gathered  by  effectors  like  p53/p21.  Previous  results  suggest  that  p53 
causes resistance of cells  to  TPT exposure (Tomicic  et  al;  2003).  Our 
findings  suggest  a PARP activation induced by TPT-dependent  double 
strand  breaks,  while  PARP-1  and  -2  inhibition  switches  on  p53  pro-
apoptotic role.
Indeed,  caspase-dependent  PARP-1  proteolysis  contributes  to 
restoring the apoptotic program in neoplastic cells and has been described 
in  camptothecin-induced  apoptosis  as  an  early event  that  precedes  the 
mitochondrial release of cytocrome c and AIF (Rodriguez-Hernandez et  
al; 2006).
In  conclusion,  our  findings  contribute  to  the  understanding  the 
molecular events triggered by TOP1 poisons-dependent genomic damage 
and  the  confirming  the  potential  of  PARP  inhibitors  as  adjuvant  of 
chemotherapy.
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1. Introduction
The camptothecin derivative topotecan (TPT) is a DNA
topoisomerase 1 (TOP1) inhibitor approved for the treatment of
ovarian cancer, non small-cell lung cancer and under clinical
investigation for a number of advanced solid tumours and
haematological malignancies [1]. The drug reversibly abolishes
the DNA religation activity of TOP1 generating single strand breaks
(SSBs) to which the protein is covalently linked. Double strand
breaks (DSBs) arise when replication forks collide with the SSBs
and run off. Thus, TPT-induced DSBs are largely replication
dependent or S phase speciﬁc [2,3].
Eukaryotes have two pathways for repairing DSBs: homologous
recombination (HR) and non homologous end joining (NHEJ). The
relative contribution of these two DSB repair pathways seems to
differ depending on the cell cycle phase; HR acts mainly in the S
and G2 phases, whereas NHEJ actsmainly in the G1 phase [4,5]. For
these reasons, TPT-induced replication-dependent DSBs are
usually repaired by the HR pathway [6].
Poly(ADP-ribosyl)ation is a post-translational modiﬁcation
catalyzed by poly(ADP-ribose)polymerase-1 and -2 (PARP-1 and
PARP-2) and is one of the earliest cellular responses to DNA
damage. PARP-1 and PARP-2 belong to a family of enzymes that
cleave b-NAD+ in nicotinamide and ADP-ribose to form long and
branched (ADP-ribose) polymers (PAR) on glutamic acid residues
within the primary sequence of PARP-1 and PARP-2 (automodi-
ﬁcation) and of other cellular proteins (heteromodiﬁcation). This
process causes chromatin decondensation around damage sites,
recruitment of repair machineries, such as base excision repair
complexes, and accelerates DNA damage repair [7,8]. In contrast,
when DNA damage exceeds cell repair capacity PARP-1 undergoes
cleavage by caspases into two fragments of 89 kDa and of 24 kDa,
thereby avoiding futile cycling of PAR that would otherwise
deplete the cell of b-NAD+ required for the onset of apoptosis [9].
Moreover, interaction of PAR with the p53 oncoprotein is able to
modulate its transcriptional activity [10].
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Amolecular approach to enhance the antitumour activity of topoisomerase 1 (TOP1) inhibitors relies on
the use of chemical inhibitors of poly(ADP-ribose)polymerases (PARP). Poly(ADP-ribosyl)ation is
involved in the regulation of many cellular processes such as DNA repair, cell cycle progression and cell
death. Recent ﬁndings showed that poly(ADP-ribosyl)ated PARP-1 and PARP-2 counteract camptothecin
action facilitating resealing of DNA strand breaks. Moreover, repair of DNA strand breaks induced by
poisoned TOP1 is slower in the presence of PARP inhibitors, leading to increased toxicity.
In the present study we compared the effects of the camptothecin derivative topotecan (TPT), and the
PARP inhibitor PJ34, in breast (MCF7) and cervix (HeLa) carcinoma cells either PARP-1 proﬁcient or
silenced, both BRCA1/2+/+ and p53+/+.
HeLa and MCF7 cell lines gave similar results: (i) TPT-dependent cell growth inhibition and cell cycle
perturbation were incremented by the presence of PJ34 and a 2 fold increase in toxicity was observed in
PARP-1 stably silenced HeLa cells; (ii) higher levels of DNA strand breaks were found in cells subjected to
TPT + PJ34 combined treatment; (iii) PARP-1 and -2 modiﬁcation was evident in TPT-treated cells and
was reduced by TPT + PJ34 combined treatment; (iv) concomitantly, a reduction of soluble/active TOP1
was observed. Furthermore, TPT-dependent induction of p53, p21 and apoptosis were found 24–72 h
after treatment and were increased by PJ34 both in PARP-1 proﬁcient and silenced cells. The
characterization of such signaling network can be relevant to a strategy aimed at overcoming acquired
chemoresistance to TOP1 inhibitors.
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PARP-1 also affects DSBs repair as indicated by the increased
sensitivity of PARP-1-deﬁcient cells to DSBs inducing agents,
especially to camptothecin [2]. Furthermore, the molecular
mechanisms underlying tumour chemosensitization to TOP1
poisons by PARP inhibitors have been in part clariﬁed by recent
ﬁndings showing that poly(ADP-ribos)ylated PARP-1 and PARP-2
counteract camptothecin action facilitating resealing of DNA
strand breaks [11]. This occurs through noncovalent yet speciﬁc
interaction of PAR with particular TOP1 sites which results in
inhibition of DNA cleavage and stimulation of the religation
reaction [12]. Another mechanism proposed to explain the
potentiation of camptothecin cytotoxicity by PARP inhibitors, is
via the inhibition of base excision repair system, of which PARP-1
and -2 are important components. This model is supported by the
association of tyrosyl phosphodiesterase-1, which removes the
TOP1 cleavable complex, with base excision repair components
that interact with PARP-1 [13].
Indeed, PARP-1 inhibition enhances the cytotoxic effects of TPT
[14]. The potential of PARP inhibitors to increase the efﬁcacy of
chemotherapy has led to the development of a wide range of
speciﬁc inhibitors – quinazolinone derivates – like NU1025 or PJ34
which display increased potency compared to the prototype 3-
aminobenzamide (3-ABA) [15]. In this regard, we previously
demonstrated a TPT-dependent PARP-1 activation in glioblastoma
cells, while co-treatment with the PARP inhibitor NU1025
increased the TPT-dependent p53 up-regulation [16]. Moreover,
we showed PJ34 chemo-potentiation of cisplatin in colon
carcinoma cells [17].
It has been reported that PARP inhibitors would be particularly
effective in BRCA1/2 mutated breast carcinoma cells [18]. In fact,
PARP-1 and PARP-2 are required for the base excision repair
pathway, whereas the BRCA proteins are critical for the HR
pathway. Cells can survive when one repair system breaks down,
but they start to die when both DNA repair mechanisms stop
functioning.
Furthermore, a factor supposed to be involved in determining
the sensitivity of cells to TOP1 inhibitors is p53. However, for
breast cancer cells the p53 status was not found to be predictive of
sensitivity to camptothecins [19].
On the basis of such evidences, we have investigated the role of
PARP-1 in the DNA damage response to TOP1 inhibitors, in human
BRCA1/2+/+ and p53+/+ mammary (MCF7) and cervix (HeLa)
carcinoma cells treated with TPT as single agent or in association
with a PARP inhibitor. Furthermore, TPT sensitivity of HeLa cells in
which PARP-1 has been knocked down by RNA interference, has
been compared to that of HeLa cells treatedwith the PARP inhibitor.
2. Materials and methods
2.1. Drugs, antibodies and chemicals
TPT was from Glaxo Smith-Kline (Verona, Italy) and PJ34 [N-(6-
oxo-5,6,-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)aceta-
mide] from Alexis Biochemicals (Vinci-Biochem, Firenze, Italy).
The cocktail of protease inhibitors was from ROCHE-Diagnostic
(Milano, Italy).
Nicotinamide adenine [adenylate-32P] dinucleotide-[32P]-NAD+
(1000 Ci/mmol, 10 mCi/ml) was supplied by GE Healthcare
(Milano, Italy).
Propidium iodide (PI) and RNAse were from Sigma–Aldrich
(Milano, Italy).
PVDF (poly-vinylidene-ﬂuoride) membrane was from MILLI-
PORE S.p.A. (Milano, Italy). Anti-PARP-1 mouse monoclonal anti-
body (F1–23) was from Alexis Biochemicals (Vinci-Biochem,
Firenze, Italy) and anti-DNA TOP1 antibody from ABCAM, (Cam-
bridge, UK). Anti-p53 (DO-1), anti-p21 (C-19), anti-BAX (P-19) and
anti-GAPDH (H-2) mouse monoclonal antibodies were from Santa-
Cruz Biotechnology (DBA, Milano, Italy); anti-actin (A2066) mouse
monoclonal antibody and goat anti-mouse and goat anti-rabbit IgG
HRP-conjugated antibodies were from Sigma–Aldrich (Milano,
Italy). Anti-gH2AX (ser139, 2577) rabbit antibody was from Cell
Signaling (Invitrogen Milano, Italy).
All other chemicals were of the highest quality commercially
available.
2.2. Cell cultures
Cervix (HeLa) and mammary (MCF7) carcinoma cells were
maintained in Dulbecco’s modiﬁed eagle’s medium (DMEM)
containing 10% (v/v) heat-inactivated foetal bovine serum (FBS),
100 U/ml penicillin, 100 mg/ml streptomycin, 5 mM L-glutamine
and incubated at 37 8C in a humidiﬁed atmosphere, plus 5% CO2.
Stably PARP-1 silenced HeLa cells (hereafter referred to as
HeLaSiP-1) or transfected with the pBabe vector carrying the
puromycin resistance gene (hereafter referred to as HeLaBabe) were
obtained as previously described [20].
2.3. Cell growth inhibition
MCF7 and HeLa cells were seeded at 1  105 cells; after 24 h,
cell cultures were treated with graded concentrations of TPT and
PJ34 and cell growth inhibition was assessed at different time
points (24, 48, 72 h) using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay. All the experiments
were performed in triplicate.
2.4. Cytoﬂuorimetric analysis
Control and treated cells were detached by enzymatic
treatment (trypsin/EDTA 0.02%), washed in PBS (w/o) Ca++/Mg++
pooled with ﬂoating cells and recovered by centrifugation at
1200 rpm for 15 min at 4 8C. Cells were ﬁxed in 70% ethanol and
stored at 20 8C until analysis. After washing in PBS (w/o) Ca++/
Mg++, cells were stained in 2 ml of propidium iodide (PI) staining
solution [50mg/ml of PI, 1 mg/ml of RNAse A in PBS (w/o) Ca++/
Mg++, pH 7.4] overnight at 4 8C and DNA ﬂow cytometry was
performed in duplicate by a FACScan ﬂow cytometer (Becton
Dickinson Franklin Lakes, NJ, USA) coupled with a CICERO work
station (Cytomation). Cell cycle analysis was performed by the
ModFit LT software (Verity Software House Inc., Topsham, ME,
USA). FL2 area versus FL2 width gating was done to exclude
doublets from the G2/M region. For each sample 15,000 events
were stored in list mode ﬁle.
2.5. Alkaline comet assay
Cells were suspended in PBS at a density of 104 cells/ml and
mixedwith an equal volume of fresh low-melting agarose (LMA, 1%
in PBS); 80 ml of agarose cell suspension was spread on normal-
melting agarose (NMA, 1% in PBS) slides and covered with a cover-
slip. Two slides were prepared per sample. After gelling for 5 min
on an ice bed, the cover-slip was gently removed and another layer
was added, cover-slipped and allowed to solidify for 5 min on ice
before gently removing the cover-slip. The slides were then
immersed in a freshly prepared ice-cold lysis solution (2.5 M NaCl,
0.1 MNa2EDTA, 0.01 MTris, 1% Triton X-100, 10%DMSO, pH 10) for
1 h. The slides were drained and placed in a horizontal
electrophoresis tank ﬁlled with freshly prepared alkaline buffer
(0.3 M NaOH, 1 mM Na2EDTA, pH 13). Electrophoresis was carried
out in this buffer for 20 min at 300 mA. Finally, the slides were
gently washed twice in a neutralization buffer (Tris–HCl 0.4 M, pH
7.5) for 5 min to remove alkali and detergent, and stained with
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50 ml/ml DAPI (3 h). Images of a minimum of hundred cells from
each sample were analysed on a ﬂuorescence microscope (Nikon
Instruments S.p.A. Firenze, Italy); overlapping ﬁgures were
avoided from each slide. Quantitative assessment of DNA damage
was performed using Comet Score 1.5 Image Analysis (TriTek
Corporation, Sumerduck, VA, USA) software which computes the
integrated intensity proﬁle for each cell. DNA damage was
measured as olive tail moment [(tail mean  head mean)  % of
DNA in the tail/100]. The results were analysed by Student’s t-test
and were considered statistically signiﬁcant at P < 0.008.
2.6. Analysis of [32P]-PAR synthesis
Following treatment with 10 mM TPT  5 mM PJ34 of intact cell
(5  106 cells/plate), [32P]-PAR synthesis was determined by substi-
tuting the culture medium with 1 ml of 56 mM HEPES buffer pH 7.5,
containing 28 mM KCl, 28 mM NaCl, 2 mM MgCl2, 0.01% digitonin,
0.1 mM PMSF, 1:25 dilution of a cocktail of protease inhibitors,
0.125 mM NAD+ and 5 mCi [32P]-NAD+ (1000 Ci/mmol). After
incubation at 37 8C for 30 min, cells were scraped off the plates,
transferred to Eppendorf tubes andmixed with TCA at 20% (w:v) ﬁnal
concentration. After 15 min standing on ice, samples were collected
by centrifugation at 1200 rpm for 15 min, washed twice with 5% TCA
and three times with ethanol. [32P]-PAR incorporated in the TCA-
insoluble fraction was measured by Cerenkov counting using a
LS8100 liquid scintillation spectrometer (Beckman Coulter S.p.A.
Milano, Italy). Finally, TCA protein pellets were resuspended in
Laemmli buffer; proteins were separated by 5–15% SDS-PAGE and
after electroblotting on PVDF membrane, [32P]-PAR acceptors were
visualized by autoradiography. Immunodetection of speciﬁc proteins
was accomplished on the same blots after autoradiography.
PJ34 efﬁciency as PARP inhibitor, was determined in an in vitro
enzymatic activity assay using permeabilized cells: cell pelletswere
resuspended in 40mM Tris–HCl pH 7.8, 0.6 mM EDTA, 30 mM
MgCl2, 0.05% Triton X-100, 1 mMb-mercaptoethanol, 20% glycerol,
1 mMPMSFanda 1:25dilution of the cocktail of protease inhibitors.
To maximally stimulate PAR synthesis, DNA strand breaks were
induced by sonication for 30 s atmedium intensity; ﬁnally, samples
were incubatedat30 8C for1 hwith5mCi/ml [32P]-NAD+and50mM
unlabeled b-NAD+, in the presence or absence of 5mM PJ34.
Reactions were stopped by TCA addition (20% ﬁnal concentra-
tion) and the samples were processed and analysed as described
above.
2.7. Isolation of nuclear and post-nuclear fractions
To isolate sub-cellular fractions, cells were suspended in a
buffer containing 30 mM Tris–HCl pH 7.5, 1.5 mM MgCl2, 10 mM
KCl, 1% (v/v) Triton X-100, 20% glycerol, 2 mM PMSF and the
protease inhibitors cocktail solution. After 30 min of incubation on
ice, cellular suspensionswere centrifuged at 960  g for 90 s at 4 8C
and the nuclear fractions recovered in the pellet. The supernatant
represents the post-nuclear fraction.
Nuclear fractions were resuspended in 20 mM HEPES pH 7.9,
containing 20 mM KCl, 0.2 mM EDTA, 1.5 mM MgCl2, 25% glycerol
and the protease inhibitors cocktail solution. Protein concentration
was determined using the Bradford protein assay reagent (BIO-
RAD, Milano, Italy) with bovine serum albumin as a standard.
2.8. Autoradiographic and immunological analyses
Aliquots of 120mg of cellular proteins were separated by SDS-
PAGE (5–15% gradient gels) and transferred onto a PVDFmembrane
using an electroblotting apparatus (BIO-RAD). The membrane was
subjected to autoradiographic analysis by the PhosphorImager
(BIO-RAD) and/or to immunodetection after blocking with 5% non-
fatmilk in TBST 1 h,with anti-PARP-1 (F1–23; diluted 1:5000), anti-
TOP1 (Scl-70; diluted 1:2500), anti-p53 (DO-1; diluted 1:5000),
anti-p21 (C-19;diluted1:1000), anti-Bax (P-19;diluted1:500), anti-
GAPDH (H2; diluted 1:5000), anti-gH2AX (2577; diluted 1:1000)
and anti-actin (A2066; diluted 1:1000).
As secondary antibodies goat-anti-mouse or goat-anti-rabbit
IgG HRP-conjugate (diluted 1:10,000–1:20,000) in 3% (w/v) non-
fat milk in TBST were used. Peroxidase activity was detected
using the ECL Advance Western blotting kit of GE Healthcare
(Milano, Italy) and quantiﬁed using the Chemiluminescent
detection system GS710 (BIO-RAD) and the Quantity One
software: the arbitrary densitometric units were normalised
on those of the GAPDH loading control.
3. Results
3.1. Effect of PJ34 on TPT-induced growth inhibition in human
carcinoma cells
In preliminary experiments human cervical (HeLa) and
mammary (MCF7) carcinoma cell lines showed comparable TPT-
dependent growth inhibition, as measured by the MTT assay (data
not shown). Furthermore, PARP-1 silencing by stable shRNA
expression in HeLa cells (HeLaSiP-1) rendered these cells more
sensitive to the cytotoxic effects of the drug. In particular, while in
a 72 h assay, 10 mMTPT for 1 h exerted mainly cytostatic effects in
control cells (HelaBabe), the same treatment caused 45% (5) of
PARP-1 silenced cells (HeLaSiP-1) to die. In the presence of 5 mM PJ34
30% (6) of PARP-1 proﬁcient and 60% (9) of PARP-1 deﬁcient cells
underwent cell death (data not shown).
To gain insight into the mechanism of enhanced TPT toxicity
as a consequence of alteration of the cellular poly(ADP-
ribosyl)ation status, we analysed cell cycle distribution at
different recovery times after 1 h exposure to increasing
concentrations of TPT, in the presence or absence of a functional
PARP-1 (i.e., PARP-1 wild type HeLa or MCF7 cells versus
HeLaSiP-1 cells). In another set of experiments, the PARP inhibitor
PJ34 was used in combination with TPT, at a ﬁxed concentration
of 5 mM, maintained in the culture medium all over the recovery
time. As shown in Fig. 1, as early as 24 h after treatment, graded
concentrations of TPT induced a progressive increase of cell
accumulation in the G2/M phase starting from 0.2 mM up to
1.25 mM. Higher TPT concentrations, instead, promptly arrested
the cells in S phase.
The addition of the PARP inhibitor PJ34 to TPT concentrations
<1.25 mM signiﬁcantly increased G2/M cell accumulation, where-
as when combined with 1.25 mM TPT concentrations, PJ34
induced S phase cell accumulation. As also shown in Fig. 1 cell
cycle kinetics was unaffected by treatment of HeLaBabe cells with
PJ34 used as single agent.
HeLaSiP-1 cells treated with TPT concentrations comprised
between 0.2 and 0.4 mM underwent a more pronounced increase
of G2/M cell accumulationwith respect to HelaBabe cells exposed to
the same concentrations of the TOP1 poison. Interestingly, 0.4 mM
TPT caused in HeLaSiP-1 cells effects comparable to those observed
in HeLaBabe cells treated with 0.4 mM TPT plus the PARP inhibitor.
However, PARP-1 silenced cells retained sensitivity to PJ34 and the
combination 1.25 mMTPT + PJ34 caused S phase accumulation at a
higher extent in HeLaSiP-1 than in HelaBabe cells (Fig. 1).
Cytoﬂuorimetric analyses at a longer recovery time (i.e., 72 h
after treatment), revealed that alterations of the poly(ADP-
ribosyl)ation system caused TPT to be cytotoxic at a concentra-
tion (1.25 mM) that was primarily cytostatic in control cells, as
indicated by the appearance of a sub-diploid peak (apoptotic
cells) both in PARP-1 silenced (HeLaSiP-1) and PJ34-treated PARP-
1 wild type cells (HelaBabe) (Fig. 2). In this regard, the lack of
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PARP-1 appeared to be more effective than PARP activity
inhibition as the fraction of apoptotic cells was 62% in TPT-
treated HeLaSiP-1 versus 38% in HeLaBabe, subjected to a combined
TPT + PJ34 treatment (Fig. 2).
3.2. Analysis of TPT and/or PJ34 dependent DNA damage in carcinoma
cells
By alkaline comet assay, we analysed the level of both SSBs and
DSBs [21] induced by 10mMTPT  PJ34 treatments. Fig. 3(A) shows
that the olive tail moment determined for both HeLa (Babe and SiP-1)
andMCF7 cells 24 h after 1 h treatment with TPTwas increased in the
cells left to recover in the presence of PJ34. The deﬁnition of a DSBs
level was obtained by looking at the H2AX phosphorylation in
isolated nuclei from Babe and SiP-1 cells. Fig. 3(B) shows that 72 h
after 1 h treatment TPT induced a higher level of histone phosphory-
lation in HeLaSiP-1 than in HelaBabe cells. H2AX phosphorylation was
further incremented by PJ34 addition in both PARP-1 proﬁcient and
silenced cells.
3.3. Analysis of PAR synthesis in carcinoma cells after treatment with
TPT  PJ34
First, PJ34 efﬁcacy as a PARP inhibitor at the concentration
used in this study was assessed in an in vitro enzyme activity
assay by incubating permeabilized and sonicated HeLa cells with
exogenous 50 mM [32P]-NAD+ in the presence or absence of 5 mM
PJ34. Sonication was performed to induce DNA strand breaks and
Fig. 1. Cell cycle analysis of HeLaBabe and HeLaSiP-1 cells treated with TPT and PJ34 as single agents or in combination. Babe and SiP-1 cells were treated for 1 h with TPT
(0.2–0.4–1.25–2.5–5 mM) in combination or not with PJ34 (5 mM) and left to recover for 24 h in fresh medium in the presence or absence of PJ34. The results are
expressed as percentages of cells in the G1, S and G2/M phase of the cell cycle. Data refer to one out of three experiments giving similar results.
Fig. 2. Cell death analysis of HeLa cells subjected to TPT and PJ34 single and combined treatments. Babe and SiP-1 cells were treated for 1 h with 1.25 mMTPT in combination
or notwith 5 mMPJ34 and left to recover for 72 h in freshmedium in the presence or absence of PJ34. Flow cytometric determination of DNA content after PI staining is shown.
The percentage of cells in the sub-diploid (subG1) peak is indicated. Data refer to one out of three experiments giving similar results.
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thus maximally stimulate endogenous PARP activities. PAR
synthesis on protein acceptors was analysed by SDS-PAGE
followed by electroblotting onto PVDF membrane and autoradi-
ography. As shown in Fig. 4(A), a high amount of protein-bound
PAR was produced in HeLa cells and such an activity was
completely inhibited by 5 mM PJ34. Although a wide range of
modiﬁed proteins could be visualized, the main PAR acceptor
was most likely PARP-1 as suggested by the strong radioactivity
signal at the top of the gel and by the concomitant reduction of
the PARP-1 immunoreactive band in the sample incubated with
b-NAD+ alone compared to that incubated with b-NAD+ and PJ34
(Fig. 4(B)). Such a difference is explained by a band depletion due
to the automodiﬁcation-related electrophoretic mobility shift of
a fraction of heavily poly(ADP-ribosylated) PARP-1. After
quantiﬁcation of immunoreactive bands by scanning
densitometry and normalization of PARP-1 to GAPDH content
it could be estimated that about 50% of PARP-1 underwent
automodiﬁcation.
The same kind of analysis carried out in HeLaSiP-1 cells, revealed
a strongly reduced ADP-ribosylation capacity of these cells as a
consequence of PARP-1 silencing (Fig. 4(A)): on the autoradiogra-
phy only a light smear at the top of the gel could be visualized. As
no PARP-1 could be detected in these cells by Western blotting
(Fig. 4(B)) the modest ADP-ribosylation activity detected by the in
vitro assay may be due to PARP-2 and/or other PARP.
Then, we used a different experimental setting to determine
whether or not TPT could induce PARP(s) activation in intact cells.
To this purpose, growingMCF7 cellswere ﬁrst exposed to the drugs
and then PAR synthesis was measured in situ by incubation in the
presence of 0.01% digitonin and 0.125 mM [32P]-NAD+. By
autoradiography (Fig. 5(A)) we observed a main signal slightly
up to PARP-1 molecular weight (113 kDa), indicating that DNA
damage induced by TPT caused PARP-1 activation and automo-
diﬁcation that was apparent already after 1 h treatment and
further increased in the following 24 h recovery time. Such a trend
was conﬁrmed by scanning densitometry and normalization of
data from autoradiography (Fig. 5(A)) to those relative to PARP-1
immunoreactive band (Fig. 5(B)). Minor autoradiographic bands
were evident in the 90–50 kDa MWs range (Fig. 5(A)) indicating
other PAR acceptors, possibly including other PARP. PARP-2 was
detectable in this region as a 62 kDa protein band; a modiﬁcation-
related electrophoretic mobility shift could explain the lack of
correspondence between the autoradiographic signal (Fig. 5(A))
and the PARP-2 immunoreactive band (Fig. 5(B)).
The autoradiographic signals were drastically reduced (up to
75% reduction) in cells co-treated with TPT and the PARP inhibitor
with respect to cells treated with TPT as single agent.
Similar results were obtained in HeLaBabe cells, while a [32P]-
PAR signal was undetectable in HeLaSiP-1 (data not shown).
3.4. Immunological analysis of PARP-1, TOP1, p53, p21 level in
TPT  PJ34 treated cells
By Western blotting we analysed changes in the endogenous
levels of PARP-1, TOP1 and p53 in HeLa and MCF7 cells at different
times (24, 48 and 72 h) after treatment with TPT  PJ34.
Fig. 6 shows a comparable amount of PARP-1 in MCF7 cell
samples at all time points, whereas the amount of soluble/active
TOP1 was lowered (50%) till 72 h after treatment with TPT alone
or in combination with PJ34. Conversely, an up-regulation of p53
endogenous levels was evident until 72 h after treatment with
TPT  PJ34. Furthermore, the p53-dependent p21 induction was
evidenced starting from 24 h after TPT treatment.
Fig. 7 shows that the amount of soluble/active TOP1 was
drastically lowered also in HeLa cells (up to 70–80% reduction both
in PARP-1 proﬁcient and silenced cells) as a consequence of the
treatments. Interestingly, such a decrease was sustained till 72 h
after 1 h treatment.
Fig. 3. DNA damage in HeLaBabe, HeLaSiP-1 and MCF7 cells subjected to TPT  PJ34
treatment. (A) Hundred cells 24 h after 1 h treatment with 10 mM TPT  5 mM PJ34
were analysed by alkaline comet assay on a ﬂuorescence microscope (Nikon) and
quantitative assessment of DNA damage was performed using Comet Score. The olive
tail moment is reported as a mean of three different experiments  S.E. (B) Western
blot analysis of gH2AX levels in HeLaBabe and HeLaSiP-1 cell nuclei treated 1 h with
10 mMTPT and allowed to recover in freshmedium in the presence or absence of 5 mM
PJ34 for 72 h. Actin was used as loading control.
Fig. 4. PJ34-dependent inhibition of PAR synthesis in HeLaBabe and HeLaSiP-1 cells.
Cells were resuspended in lysis buffer, sonicated and incubated with 50mM [32P]-
NAD+  5 mM PJ34 as described in Section 2. (A) Autoradiographic analysis of whole
cell protein after SDS-PAGE and electroblot on PVDF. (B) Immunodetection of PARP-1
and GAPDH on the blot shown in (A).
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Again, we observed a TPT-dependent p53 up-regulation in both
PARP-1 proﬁcient and silenced cells, which appeared further
increased by the use of PARP inhibitor (Fig. 7).
By densitometric scanning of immunoreactive bands we
quantiﬁed the changes in p53 levels at different times after
single and combined treatments. As shown in Fig. 8, the p53 level
was 2–4 fold increased in HeLaBabe cells 72 h after 1 h TPT  PJ34
treatment. In HeLaSiP-1 cells a 10 fold increase was induced by TPT
alone and this value increased (13 fold) in thepresence of PJ34 during
the recovery time.
Finally, 72 h after TPT treatment we analysed the expression of
apoptotic markers. Fig. 9 shows in HeLaBabe cells the caspase-
dependent PARP-1 cleavage. In MCF7 cells, instead, the PARP-1
apoptotic fragment was hardly detectable but we observed the
p53-dependent expression of BAX. Interestingly, we found that
PJ34 was able to enhance both such apoptotic signals.
4. Discussion
The evaluation of PARP inhibitors as chemosensitizers is based
on evidences linking PARP-1 and recently PARP-2, to the cellular
DNA damage response [13]. This has led to the development of a
multitude of potent inhibitors with various bioavailability and
pharmacokinetic characteristics whose efﬁcacy in the treatment of
cancer in vivo has been evaluated in animal models [14,22];
several PARP inhibitors are currently under investigation in clinical
trials [15,23]. However, a clear understanding of themechanism(s)
whereby PARP inhibitors potentiate the activity of antineoplastic
agents is still lacking. Moreover, isoform speciﬁc PARP inhibitors
are still missingwhile it is known that PARP-2 accounts for 10–20%
of the total PARP activity in response to DNA damage [24 and
references therein].
In our studies we used the hydrophilic PARP inhibitor PJ34 that
has been recently reported to synergize with cisplatin in triple-
negative breast cancer cells [25], in combinationwith theDNATOP1
inhibitor, TPT. For our experiments we performed 1 h treatment
with up to 10mM TPT that was already reported to be sufﬁcient for
trapping TOP1 in MCF7 cells [26]. PJ34 was used at a concentration
(5mM) that was capable of inhibiting PARP activity but devoid of
cytotoxic effects we found that TPT toxicity was higher when PAR
synthesiswas strongly reducedbyeitherPARP-1silencing (HeLaSip-1
cells) or PJ34 administration (both in HeLa and MCF7 cells).
MCF7 and HeLa cells, accordingwith their comparable PARP-1+/
+ BRCA1/2+/+ and p53+/+ status showed the same sensitivity to TPT,
which determined a cell cycle arrest until 72 h after treatment.
However, in combination with PJ34, TPT was cytotoxic even at a
very low concentration (1.25mM). Accordingly, 1.25 mMTPT alone
was cytotoxic in PARP-1 silenced cells (HeLaSiP-1). Nevertheless,
the PARP inhibitor further increased the sensitivity of SiP-1 cells
with respect to PARP-1 proﬁcient cells treated with the drug
combination, suggesting a PARP-2 involvement in the signaling of
TPT-dependent DNA damage.
Consistently with the idea that poly(ADP-ribosyl)ation plays a
role in the response to TPT-induced DNA damage, we found
Fig. 6.Western blot analysis of PARP-1, TOP1, p53 and p21 inMCF7 cells. Cells were treatedwith 10 mMTPT for 1 h and allowed to recover in freshmedium in the presence or
absence of 5mM PJ34 for the indicated times. GAPDH was used as loading control.
Fig. 5. TPT-dependent PARP activation inMCF7 cells. Following treatmentwith 10 mMTPT  PJ34 and recovery for 24 h in freshmedium in the presence or absence of 5 mMPJ34,
cells were incubated with 0.125 mM [32P]-NAD+, as described in Section 2. (A) Autoradiographic analysis of whole cell protein after SDS-PAGE and electroblot on PVDF. (B)
Immunodetection of PARP-1, PARP-2 and GAPDH on the blot shown in (A). Fifty ng of human recombinant PARP-2 (hrPARP-2) was also loaded as a standard.
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increased PAR synthesis following cell exposure to 10 mMTPT. The
PARP inhibitor PJ34 prevented PARP activity and concomitantly
caused intensiﬁcation of cell cycle perturbations and increased
DNA damage.
In particular, we observed distinct cell cycle perturbation
effects depending on the concentration of the TOP1 inhibitor and
on the association with the PARP inhibitor: in the low TPT dose
range, PJ34 in combination with 0.2–0.4mMTPT causedmore cells
to be arrested in the G2/M phase, whereas combinedwith 1.25mM
TPT it arrested at the S phase cells that escaped TPT action.
Furthermore, the G2/M block induced by 0.4 mM TPT in PARP-1
wild type cells was magniﬁed in PARP-1 silenced HeLa cells. These
evidences agreewith the concept that after 1 h pulse (whatever the
dose) of TPT not all the cells are prevented from entry in mitosis
and then G2 cell lineages could survive TPT-mediated cytotoxicity
[27]. Therefore, accumulation at the G2/M phase of tumour cells
that escaped TPT action, provoked by PARP inhibition or by PARP-1
silencing, can be seen as a mechanism to overcome resistance to
camptothecin derivatives. Interestingly, in PARP-1 silenced HeLa
cells PJ34 increased the TPT S phase arrest as a further indication of
PARP-2 implication.
Consistently, the TPT-dependent DNA damage level was
increased by co-treatment with PJ34 both in PARP-1 proﬁcient
and PARP-1 silenced cells 24 h after treatment. In nuclei of such
cells, differences in gH2AX levels deriving from TPT  PJ34, also
support PARP-1 and -2 stimulation of TPT-dependent DSBs repair.
Moreover, we found a sustained PAR synthesis from 1 to 24 h
after treatment and most of the newly synthesized polymer was
linked to PARP-1 itself. Two other PAR acceptors in the 55–95 kDa
MW’s range appeared to be TPT- and PJ34-dependent. Accordingly
with the magniﬁed effects of TPT + PJ34 treatment in PARP-1
silenced cells the PARP-2 modiﬁcation could represent the mecha-
nism of its participation in DSBs signaling and HR repair [24].
Indeed, these evidences suggest that the lack of PAR synthesis,
by interfering with the repair of TOP1-induced DNA damage,
causes DNA strand breaks accumulation and further delays cell
cycle progression. Moreover, we found that TPT-treated cells
entered the apoptotic program as a consequence of PARP-1
silencing and/or PARP inhibition.
The last set of results was based on mechanistic investigations
addressed to show the long-term response to TPT action: after 1 h
TPT pulse TOP1 soluble/active fraction was drastically reduced for
at least 3 cell duplication cycles and p53/p21 levels increased
within the same time frame. Such an up-regulation was even
higher in cells lacking PARP-1 and further increased by TPT + PJ34
treatment, supporting again the involvement of PARP-2 in the
signaling of TPT-dependent DNA damage.
These results are in agreement with those previously reported
in the same cells treatedwith themethylating agent temozolomide
in combination with the PARP inhibitor GPI 15427, suggesting the
involvement of PARP-2 (or other PARP) in the repair of DNA
damage provoked by temozolomide [20].
Fig. 8. Densitometric analysis of p53 levels in HeLa cell samples. After
immunodetection on Western blots, band intensities were quantiﬁed by
scanning densitometry. Data, expressed as arbitrary densitometric units (ADU),
were normalized to the internal control GAPDH. Shown are the mean of three
different experiments  S.E.
Fig. 7.Western blot analysis of PARP-1, TOP1, p53 and p21 inHeLaBabe andHeLaSiP-1 cells. Cells were treatedwith 10mMTPT for 1 h and allowed to recover in freshmedium in
the presence or absence of 5mM PJ34 for the indicated times. GAPDH was used as loading control.
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Our data also suggest a synergistic interaction of PARP-1 and
PARP-2 with p53 in tumour suppression through their role in DNA
damage response and genome integrity surveillance. Another
study showed that in MCF7 cells inhibition of endogenous PARP-1
function suppresses the transactivation function of p53 in
response to ionizing radiation [28]. We also observed that p53-
dependent BAX expression and caspase-dependent PARP-1 prote-
olysis were sustained by the PARP inhibitor as a result of apoptosis
induction.
By the all of such evidenceswe envisaged a TPT-dependent DNA
damage signaling network, involving PARP. Indeed, the DNA
damage arising from the trapping of TOP1 was signaled by PARP-1
and -2 and gathered by effectors like p53 and p21. Previous results
suggest that p53 causes resistance of cells to TPT [29]. Our ﬁndings
suggest a PARP modiﬁcation induced by TPT-dependent DNA
damage, while PARP-1 and -2 inactivation switches on p53/p21
pro-apoptotic role.
Indeed, caspase-dependent PARP-1 proteolysis contributes to
restoring the apoptotic program in neoplastic cells. Nuclear
caspases-mediated PARP-1 cleavage has been described in
camptothecin-induced apoptosis as an early event that precedes
the release of cytochrome c and AIF, generally thought to
activate the chemotherapy-induced apoptosis by DNA-damag-
ing drugs [30].
In conclusion, our ﬁndings contribute to the understanding of
the molecular events triggered by TOP1 poison-dependent
genomic damage and provide a rationale for the development of
new approaches to sensitize cancer cells to chemotherapy.
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